Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Genuine Parts Company (GPC) vs Eli Lilly And Co (LLY) Price & Performance

Genuine Parts CompanyTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Genuine Parts Company vs Eli Lilly And Co — how do they compare? Genuine Parts Company trades at $135.22 (market cap $18.55B), while Eli Lilly And Co trades at $1,214.52 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 59.3× Genuine Parts Company's market cap, and Genuine Parts Company pays the higher dividend (3.16%). Which is the better fit depends on your goals.

GPCLLY
Market Cap
$18.55B$1.10T
Sector
Consumer CyclicalHealth
52-Week High
$149.26$1.24K
52-Week Low
$92.47$639.43
Enterprise Value
$24.64B$1.14T
Dividend Yield
3.16%0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Genuine Parts Company

GPC trades at $135.63, up 2.14% today, with a bullish technical signal from moving averages but a bearish oscillator reading. The stock is supported by strong Q2 2026 earnings beats, with sales growth of 6% year-over-year and an adjusted EPS of $2.15 beating estimates. However, net income margin remains thin at 0.13% for 2025, and the P/E ratio is elevated at 542.52, indicating high valuation relative to earnings. Recent news highlights institutional buying interest and reaffirmed 2026 adjusted EPS guidance of $7.50 to $8.00.

The outlook for GPC is cautiously optimistic, with analyst consensus pointing to a $148.67 price target and a 'Buy' rating from 43% of covering analysts. Key opportunities include sustained industrial segment strength and dividend consistency, while risks involve margin pressure from inflation, high debt levels, and competitive pressures in the auto parts industry. Earnings growth and cost management are critical for future stock performance.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Genuine Parts Company

Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.

Read more on GPC

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY